MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $71.69 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 42.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 884,985 shares of the biopharmaceutical company’s stock after acquiring an additional 264,282 shares during the quarter. Gilead Sciences makes up about 2.7% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s portfolio, making the stock its 3rd largest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Gilead Sciences were worth $71,693,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd increased its position in shares of Gilead Sciences by 7.0% during the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 121 shares during the period. Nilsine Partners LLC increased its position in shares of Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its position in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 128 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the period. Finally, Rodgers Brothers Inc. increased its position in shares of Gilead Sciences by 4.6% during the second quarter. Rodgers Brothers Inc. now owns 3,113 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 138 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at $8,709,586.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,242 shares of company stock valued at $1,277,726. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on GILD. Royal Bank of Canada cut their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. Oppenheimer cut their target price on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, February 12th. Wells Fargo & Company cut their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Barclays cut their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Finally, StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $85.36.

Gilead Sciences Stock Performance

NASDAQ GILD traded up $0.24 during trading hours on Friday, reaching $73.25. 8,369,703 shares of the company were exchanged, compared to its average volume of 7,477,960. Gilead Sciences, Inc. has a 1 year low of $71.37 and a 1 year high of $87.86. The business’s 50 day simple moving average is $74.85 and its 200-day simple moving average is $77.26. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $91.20 billion, a P/E ratio of 16.28, a P/E/G ratio of 0.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.67 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.20%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.